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Abstract
Background: Mathematical models can be used to predict the emergence and transmission of
antiviral resistance. Previously it has been predicted that high usage of antivirals (in
immunocompetent populations) to treat Herpes Simplex Virus type 2 (HSV-2) would only lead to
fairly low levels of antiviral resistance. The HSV-2 predictions were based upon the assumption that
drug-resistant strains of HSV-2 would be less infectious than drug-sensitive strains but that the
drug-resistant strains would not be impaired in their ability to reactivate. Recent data suggest that
some drug-resistant strains of HSV-2 are likely to be impaired in their ability to reactivate.
Objectives: (1) To predict the effect of a high usage of antivirals on the prevalence of drug-resistant
HSV-2 under the assumption that drug-resistant strains will be less infectious than drug-sensitive
strains of HSV-2 and also have an impaired ability to reactivate. (2) To compare predictions with
previous published predictions.
Methods:  We generated theoretical drug-resistant HSV-2 strains that were attenuated (in
comparison with drug-sensitive strains) in both infectivity and ability to reactivate. We then used a
transmission model to predict the emergence and transmission of drug-resistant HSV-2 in the
immunocompetent population assuming a high usage of antivirals.
Results: Our predictions are an order of magnitude lower than previous predictions; we predict
that even after 25 years of high antiviral usage only 5 out of 10,000 immunocompetent individuals
will be shedding drug-resistant virus. Furthermore, after 25 years, 52 cases of HSV-2 would have
been prevented for each prevalent case of drug-resistant HSV-2.
Conclusions: The predicted levels of drug-resistant HSV-2 for the immunocompetent population
are so low that it seems unlikely that cases of drug-resistant HSV-2 will be detected.
Background
Mathematical models can be used as health policy tools to
predict the emergence and transmission of antiviral resist-
ance [1–5]. These models have predicted, that if treatment
rates are high, that high levels of antiviral resistance to
HIV will arise very quickly; for example, 42% of HIV cases
in San Francisco are predicted to be infected with drug-re-
sistant strains by 2005 [3,4]. These theoretical predictions
have been compared with empirical data, and shown to
be valid [4,6]. In stark contrast to the HIV predictions, it
has been predicted that high usage of antivirals to treat
Herpes Simplex Virus type 2 (HSV-2) would only lead to
low levels of resistance (in immunocompetent popula-
tions) [1,2]. These predictions were based upon the
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assumption that drug-resistant strains of HSV-2 would be
less infectious than drug-sensitive strains, but that the
drug-resistant strains would not be impaired in their reac-
tivation ability. However, recent experience with drug-re-
sistant variants has shown that the majority of these
variants are deficient in the expression of thymidine ki-
nase [7–9], a phenotype that is known to be associated
with a reduced ability to reactivate [8–10]. Here, we mod-
el the effect of impaired reactivation ability of drug-resist-
ant strains and generate new predictions for the expected
emergence of antiviral resistance to HSV-2. We also assess
the beneficial and the potential detrimental epidemic-lev-
el effects of a high usage of antivirals by conducting a "bi-
ological cost-benefit" analysis and calculating the value of
a treatment evaluation criterion (TEC(t)). We compare
our new predictions for the expected levels of drug resist-
ant HSV-2 and TEC(t) with previous predictions.
Methods
We used a previously published mathematical model to
track the effect of a high usage of antivirals on the trans-
mission dynamics of drug-sensitive and drug-resistant
HSV-2 strains in an immunocompetent population [1,2].
We model the effect of episodic treatment on epidemic vi-
ral dynamics; hence treatment occurs only during an in-
fectious outbreak and reduces the length of the infectious
period (which reduces the possibility of transmission of
HSV-2). Thus, the greater the treatment rate (in terms of
the number of infectious episodes treated) then the great-
er the reduction in transmission. The possibility of trans-
mitted (i.e., primary) resistance emerging, as well as the
development of both temporary and permanent acquired
drug resistance are included in the model. Individuals
with permanent resistance are assumed to reactivate with
drug-resistant HSV-2 strains during each subsequent out-
break. Individuals with transient resistance are modeled
by assuming that they only present with drug resistance
during the episode in which they acquire resistance;
hence, all of their subsequent infectious outbreaks are
drug-sensitive. Details of the model, which is specified by
a series of six ordinary differential equations, are given
elsewhere [1,2]. A web-based version of this model can be
run at http://www.biomath.ucla.edu/faculty/sblower.
To generate our predictions we analyzed the model using
time-dependent uncertainty analyses [1–5], [11–13].
These analyses were based upon Latin Hypercube Sam-
pling (LHS), a sampling technique that enables us to
make predictions using a range of parameter values for
each parameter. Hence, each parameter is specified by a
probability distribution function (pdf) rather than a sin-
gle value; the pdfs that we used have been reported and
discussed previously [1]. Each pdf was randomly sampled,
without replacement, 1,000 times. Predictions were gen-
erated by simulating the model 1,000 times using the pa-
rameter values sampled by LHS; methodological details
are given elsewhere [1–5], [11–13]. We predicted the ef-
fect of 1,000 drug-sensitive strains of HSV-2 that each dif-
fered in their infectivity and reactivation ability. In terms
of infectivity, the transmission probability of drug-sensi-
tive strains was assumed to lie between 0.1 and 0.5 [1]. In
terms of reactivation ability, drug-sensitive strains were as-
sumed to cause anywhere from one to 20 (with a most
likely value of 12) viral shedding infectious episodes per
year [1]; these viral shedding episodes could be either
symptomatic or asymptomatic.
We used sampling constraints during the LHS to construct
1,000 different drug-resistant HSV-2 strains that were at-
tenuated in comparison with the drug-sensitive strains
with respect to both infectivity and reactivation ability.
The relationship βR = αβS (where α was a random variable
uniformly distributed between zero and one and βR and
βS specified the infectivity (i.e., transmission probability)
of drug-resistant and drug-sensitive strains respectively)
was used to determine the infectivity level of drug-resist-
ant strains. Attenuation in reactivation ability was derived
in a similar manner by multiplying each of the 1,000
drug-sensitive reactivation rates (that had been obtained
by LHS) by a randomly selected weighting factor (Η ;
where 0 < Η < 0.25 with uniform pdf). Since most drug-
resistant variants that have been studied are TK deficient
and are attenuated both in infectivity and reactivation
ability [7], we included sampling constraints so that infec-
tivity and reactivation ability were positively correlated.
This sampling procedure ensured that the 1,000 drug-re-
sistant strains that we constructed ranged in their reactiva-
tion ability from 0–5 reactivations per year, and that the
transmission probabilities ranged from (0.1 to 0.5) (as
shown in Figure 1).
We then simulated the model and predicted the levels of
drug resistance that would emerge, assuming that antiviral
usage was high (i.e., that 10–50% of the individuals who
were shedding virus at any particular time could receive
episodic treatment). In order to compare with previous
predictions we predicted the temporal dynamics of: (i) the
prevalence of drug-resistant infectiousness and (ii) the
value of the Treatment Evaluation Criterion (TEC(t))
where TEC(t) equals the average number of drug-sensitive
cases prevented at time t per prevalent case of drug resist-
ance [1]. Thus, a value of TEC(t) of greater than one rep-
resents a net beneficial effect of antiviral usage at the
epidemic level (i.e., more than one drug-sensitive case of
HSV-2 is prevented for each prevalent case of drug resist-
ance [1]).BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/1
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Results
The 1,000 theoretical drug-resistant strains of HSV-2 that
we constructed were attenuated in both their infectivity
and the ability to reactivate; sampling constraints ensured
that infectivity and the average number of infectious epi-
sodes per year were positively correlated (Figure 1). The
temporal dynamics of the predicted prevalence of drug-re-
sistant HSV-2 is shown in Figure 2A; blue data show the
previously published predictions [1] that assume that
drug-resistant strains would be attenuated only in infec-
tivity, and red data show the new predictions that assume
that drug-resistant strains would be attenuated in both in-
fectivity and reactivation ability. Prevalence is plotted as a
percentage of the total population, thus the maximum
value of 0.8% on the y-axis reflects 8 infections per 1,000
individuals. As has been shown previously [1], even with
very high rates of antiviral usage only low levels of drug re-
sistance are predicted to emerge even over a period of dec-
ades (blue and red data; Figure 2A). Previously (under the
assumption that drug-resistant strains will only be attenu-
ated in their ability to infect) it was predicted that only 7
in 1,000 individuals (blue data at 25 years; Figure 2A) are
expected to be shedding drug-resistant strains. However,
our new predictions that assume that drug-resistant
strains will be less infectious and less likely to reactivate
(red data; Figure 2A) are an order of magnitude lower
than these previous predictions; only 5 out of 10,000 in-
dividuals are predicted to be shedding drug-resistant virus
(red data at 25 years; Figure 2A).
Previous estimates (blue data; Figure 2B) show that even
after 25 years of high antiviral usage 4.5 cases of HSV-2
would be prevented for each prevalent case of drug-resist-
ant HSV-2. Our new results (red data) show that if the
drug-resistant strains are attenuated in both their ability to
Figure 1
Biological attributes of the 1,000 strains of drug-resistant HSV-2 that were constructed using sampling constraints and LHS. 
Strains were generated to produce a strong positive correlation between the number of infectious episodes (NE
R) and the 
transmissibility (βR) of the drug-resistant strain. The correlation coefficient (r) of this data set is 0.83.
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Figure 2
Results of the uncertainty analyses using a previously published transmission model [1,2]. Blue data are predictions published 
previously (and described in detail in reference 1) assuming that viral attenuation in drug-resistant strains reduces only infectiv-
ity (in comparison with drug-sensitive strains). Red data are the new predictions assuming that viral attenuation in the drug-
resistant strains reduces both infectivity and reactivation ability. (A) The median value of the 1,000 simulations in the uncer-
tainty analysis is plotted. The prevalence of drug-resistant infectiousness (i.e., the prevalence of the individuals who are shed-
ding drug-resistant HSV-2) is shown. (B) Predictions for the Treatment Evaluation Criterion (TEC(t)) is shown; the median 
value of the 1,000 simulations in the uncertainty analysis is plotted.
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infect and reactivate then the value of TEC would be even
greater; after 25 years 52 cases of HSV-2 would be prevent-
ed for each prevalent case of drug-resistant HSV-2.
Discussion
Here we have predicted the emergence and transmission
of antiviral resistance in the immunocompetent popula-
tion (i.e., the "general population"). More complex mod-
els could be developed to assess the emergence and
transmission of drug-resistant HSV-2 strains in a popula-
tion that contains both immunocompetent and immuno-
compromised individuals. Acquired resistance occurs
with a much greater probability in immunocompromised
individuals (in comparison with imunocompetent indi-
viduals) due to a variety of host, virological and treatment
factors [14]; hence the prevalence of resistant HSV-2 in
samples of immunocompromised individuals has already
been reported to be 4–7% [14]. It is unlikely that drug-re-
sistant HSV-2 cases in immunocompromised individuals
will lead to significant increases in drug resistance in the
immunocompetent population unless very transmissible
strains of drug-resistant HSV-2 arise and considerable sex-
ual mixing occurs between immunocompromised and
immunocompetent individuals.
Mathematical models can be very useful in predicting the
spread of antiviral resistance [1,4,15]. We have shown pre-
viously [1,2] that a substantial increase in antiviral usage
in immunocompetent populations would have a substan-
tial beneficial impact on herpes epidemics in terms of pre-
venting new infections, and have a negligible detrimental
impact in terms of generating drug resistance (i.e., TEC(t)
>> 1). Our new predictions for the emergence of drug re-
sistant HSV-2 (where we have included the assumption
that drug resistant strains of HSV-2 will have an impaired
ability to reactivate) are an order of magnitude lower than
previous predictions. Our results suggest that the very low
levels of drug-resistant HSV-2 that have been observed so-
far in the "real-world" in the immunocompetent popula-
tion [8,14] are not unexpected, and also are not likely to
increase. Given the low levels of drug resistance that are to
be expected (5 per 10,000 immunocompetent individu-
als) it seems unlikely that cases of drug-resistant HSV-2
that arise in the immunocompetent population will be
detected unless extremely large-scale surveillance systems
are put in place.
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